Cingulate closes $12M PIPE financing, appoints Jeff Hargroves to board and converts debt

Cingulate Inc.

• Cingulate completed $12M private placement led by Falcon Creek Capital at $5.04 per share with 80% warrant coverage
• Jeff Hargroves appointed as Class I director and to Audit, Compensation, and Nominating committees
• Company issued 25,786 shares at $6.16 per share to a lender in exchange for debt under Section 3(a)(9)
• All PIPE investors subject to 180-day lock-up; total potential proceeds up to $21.4 million
• FDA PDUFA target date for CTx-1301 ADHD treatment set for May 31, 2026